These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 30835122

  • 1. Microtubule-Targeting Drugs: More than Antimitotics.
    Kaul R, Risinger AL, Mooberry SL.
    J Nat Prod; 2019 Mar 22; 82(3):680-685. PubMed ID: 30835122
    [Abstract] [Full Text] [Related]

  • 2. Recent progress in discovery and development of antimitotic agents.
    Kiselyov A, Balakin KV, Tkachenko SE, Savchuk N, Ivachtchenko AV.
    Anticancer Agents Med Chem; 2007 Mar 22; 7(2):189-208. PubMed ID: 17348827
    [Abstract] [Full Text] [Related]

  • 3. Natural products as new antimitotic compounds for anticancer drug development.
    Paier CRK, Maranhão SS, Carneiro TR, Lima LM, Rocha DD, Santos RDS, Farias KM, Moraes-Filho MO, Pessoa C.
    Clinics (Sao Paulo); 2018 Dec 10; 73(suppl 1):e813s. PubMed ID: 30540125
    [Abstract] [Full Text] [Related]

  • 4. Natural products as antimitotic agents.
    Dall'Acqua S.
    Curr Top Med Chem; 2014 Dec 10; 14(20):2272-85. PubMed ID: 25434355
    [Abstract] [Full Text] [Related]

  • 5. Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton.
    Steinmetz MO, Prota AE.
    Trends Cell Biol; 2018 Oct 10; 28(10):776-792. PubMed ID: 29871823
    [Abstract] [Full Text] [Related]

  • 6. How do microtubule-targeted drugs work? An overview.
    Jordan MA, Kamath K.
    Curr Cancer Drug Targets; 2007 Dec 10; 7(8):730-42. PubMed ID: 18220533
    [Abstract] [Full Text] [Related]

  • 7. Antimitotic sulfonamides inhibit microtubule assembly dynamics and cancer cell proliferation.
    Mohan R, Banerjee M, Ray A, Manna T, Wilson L, Owa T, Bhattacharyya B, Panda D.
    Biochemistry; 2006 May 02; 45(17):5440-9. PubMed ID: 16634625
    [Abstract] [Full Text] [Related]

  • 8. Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin.
    Kuznetsov G, TenDyke K, Towle MJ, Cheng H, Liu J, Marsh JP, Schiller SE, Spyvee MR, Yang H, Seletsky BM, Shaffer CJ, Marceau V, Yao Y, Suh EM, Campagna S, Fang FG, Kowalczyk JJ, Littlefield BA.
    Mol Cancer Ther; 2009 Oct 02; 8(10):2852-60. PubMed ID: 19825803
    [Abstract] [Full Text] [Related]

  • 9. Natural antitubulin agents: importance of 3,4,5-trimethoxyphenyl fragment.
    Negi AS, Gautam Y, Alam S, Chanda D, Luqman S, Sarkar J, Khan F, Konwar R.
    Bioorg Med Chem; 2015 Feb 01; 23(3):373-89. PubMed ID: 25564377
    [Abstract] [Full Text] [Related]

  • 10. Selective Inhibition of Spindle Microtubules by a Tubulin-Binding Quinazoline Derivative.
    Sawada JI, Ishii H, Matsuno K, Sato M, Suzuki Y, Asai A.
    Mol Pharmacol; 2019 Nov 01; 96(5):609-618. PubMed ID: 31471455
    [Abstract] [Full Text] [Related]

  • 11. Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution.
    Henriques AC, Ribeiro D, Pedrosa J, Sarmento B, Silva PMA, Bousbaa H.
    Cancer Lett; 2019 Jan 01; 440-441():64-81. PubMed ID: 30312726
    [Abstract] [Full Text] [Related]

  • 12. Viriditoxin Stabilizes Microtubule Polymers in SK-OV-3 Cells and Exhibits Antimitotic and Antimetastatic Potential.
    Su M, Zhao C, Li D, Cao J, Ju Z, Kim E, Jung YS, Jung JH.
    Mar Drugs; 2020 Aug 27; 18(9):. PubMed ID: 32867174
    [Abstract] [Full Text] [Related]

  • 13. Microtubule destabilising agents: far more than just antimitotic anticancer drugs.
    Bates D, Eastman A.
    Br J Clin Pharmacol; 2017 Feb 27; 83(2):255-268. PubMed ID: 27620987
    [Abstract] [Full Text] [Related]

  • 14. Novel mitotic targets and their small-molecule inhibitors.
    Ivachtchenko AV, Kiselyov AS, Tkachenko SE, Ivanenkov YA, Balakin KV.
    Curr Cancer Drug Targets; 2007 Dec 27; 7(8):766-84. PubMed ID: 18220536
    [Abstract] [Full Text] [Related]

  • 15. Targeting mitosis for anti-cancer therapy.
    Sudakin V, Yen TJ.
    BioDrugs; 2007 Dec 27; 21(4):225-33. PubMed ID: 17628120
    [Abstract] [Full Text] [Related]

  • 16. Anticancer therapy with novel tubulin-interacting drugs.
    Kavallaris M, Verrills NM, Hill BT.
    Drug Resist Updat; 2001 Dec 27; 4(6):392-401. PubMed ID: 12030786
    [Abstract] [Full Text] [Related]

  • 17. Microtubules and actin filaments: dynamic targets for cancer chemotherapy.
    Jordan MA, Wilson L.
    Curr Opin Cell Biol; 1998 Feb 27; 10(1):123-30. PubMed ID: 9484604
    [Abstract] [Full Text] [Related]

  • 18. From Natural Products to Designer Drugs: Development and Molecular Mechanisms Action of Novel Anti-Microtubule Breast Cancer Therapeutics.
    Mahaddalkar T, Lopus M.
    Curr Top Med Chem; 2017 Feb 27; 17(22):2559-2568. PubMed ID: 28056739
    [Abstract] [Full Text] [Related]

  • 19. Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function.
    Field JJ, Kanakkanthara A, Miller JH.
    Bioorg Med Chem; 2014 Sep 15; 22(18):5050-9. PubMed ID: 24650703
    [Abstract] [Full Text] [Related]

  • 20. Mitosis is not a key target of microtubule agents in patient tumors.
    Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T.
    Nat Rev Clin Oncol; 2011 Feb 01; 8(4):244-50. PubMed ID: 21283127
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.